Nisa Investment Advisors LLC Has $1.13 Million Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Nisa Investment Advisors LLC lifted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 14,674.2% in the 4th quarter, Holdings Channel reports. The institutional investor owned 9,160 shares of the specialty pharmaceutical company’s stock after purchasing an additional 9,098 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $1,127,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. ST Germain D J Co. Inc. bought a new stake in shares of Jazz Pharmaceuticals in the second quarter worth $40,000. Covestor Ltd grew its stake in shares of Jazz Pharmaceuticals by 676.5% in the third quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock worth $51,000 after purchasing an additional 345 shares during the last quarter. Spire Wealth Management grew its stake in shares of Jazz Pharmaceuticals by 128.6% in the third quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 238 shares during the last quarter. Headinvest LLC bought a new stake in shares of Jazz Pharmaceuticals in the third quarter worth $56,000. Finally, Signaturefd LLC grew its stake in shares of Jazz Pharmaceuticals by 85.7% in the third quarter. Signaturefd LLC now owns 546 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 252 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $110.91 on Tuesday. The firm’s 50-day moving average price is $120.99 and its 200-day moving average price is $122.95. Jazz Pharmaceuticals plc has a 1-year low of $110.08 and a 1-year high of $146.70. The firm has a market capitalization of $6.99 billion, a P/E ratio of 18.12, a P/E/G ratio of 1.53 and a beta of 0.59. The company has a current ratio of 2.24, a quick ratio of 1.85 and a debt-to-equity ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.01 billion. Equities research analysts anticipate that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

Insider Activity

In related news, CAO Patricia Carr sold 1,936 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now owns 8,364 shares in the company, valued at approximately $1,000,668.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CAO Patricia Carr sold 1,936 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now owns 8,364 shares in the company, valued at approximately $1,000,668.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Philip L. Johnson bought 12,000 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was acquired at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the acquisition, the chief financial officer now directly owns 27,932 shares in the company, valued at $3,342,063.80. The disclosure for this purchase can be found here. Company insiders own 4.40% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on JAZZ. Cantor Fitzgerald reissued an “overweight” rating and issued a $180.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $195.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, February 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $220.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. Robert W. Baird assumed coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $160.00 price target on the stock. Finally, Stifel Nicolaus upped their price target on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a research report on Friday, March 15th. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $195.08.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.